Abstract
Galanin is a 29/30 amino acid peptide neurotransmitter that is widely distributed throughout the central nervous system and periphery. There are three well-characterized G-protein coupled galanin receptors subtypes (GalR1-3). A more recently discovered 60 amino acid galanin-like peptide (GALP) shares amino acid sequence homology with galanin (1-13) in position 9-21 and has high binding affinity for GalR1-3, with highest affinity for GalR3. Considerable evidence has accumulated that implicates both galanin and GALP as playing important roles in regulating food and water intake behavior and related neuroendocrine functions. Pharmacological tools are emerging that will allow dissociation of specific roles for the peptides and their associated receptor subtypes in mediating the homeostatic processes of energy and fluid balance.
Keywords: Appetite, metabolic syndrome, G-protein, hypothalamus, neuropeptide, thirst
CNS & Neurological Disorders - Drug Targets
Title: Galanin/GALP Receptors and CNS Homeostatic Processes
Volume: 5 Issue: 3
Author(s): J. K. Robinson, T. Bartfai and U. Langel
Affiliation:
Keywords: Appetite, metabolic syndrome, G-protein, hypothalamus, neuropeptide, thirst
Abstract: Galanin is a 29/30 amino acid peptide neurotransmitter that is widely distributed throughout the central nervous system and periphery. There are three well-characterized G-protein coupled galanin receptors subtypes (GalR1-3). A more recently discovered 60 amino acid galanin-like peptide (GALP) shares amino acid sequence homology with galanin (1-13) in position 9-21 and has high binding affinity for GalR1-3, with highest affinity for GalR3. Considerable evidence has accumulated that implicates both galanin and GALP as playing important roles in regulating food and water intake behavior and related neuroendocrine functions. Pharmacological tools are emerging that will allow dissociation of specific roles for the peptides and their associated receptor subtypes in mediating the homeostatic processes of energy and fluid balance.
Export Options
About this article
Cite this article as:
Robinson K. J., Bartfai T. and Langel U., Galanin/GALP Receptors and CNS Homeostatic Processes, CNS & Neurological Disorders - Drug Targets 2006; 5 (3) . https://dx.doi.org/10.2174/187152706777452281
DOI https://dx.doi.org/10.2174/187152706777452281 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview
Current Drug Targets Snapshots of Protein Folding Problem: Implications of Folding and Misfolding Studies
Protein & Peptide Letters Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets The Anterior-posterior Functional Connectivity Disconnection in the Elderly with Subjective Memory Impairment and Amnestic Mild Cognitive Impairment
Current Alzheimer Research Classification of Acetylcholinesterase Inhibitors and Decoys by a Support Vector Machine
Combinatorial Chemistry & High Throughput Screening Pre-Dementia Diagnosis of Alzheimers Disease: Translating Clinicobiologic Research into Practice
Current Psychiatry Reviews Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology Ferric Cycle Activity and Alzheimer Disease
Current Neurovascular Research β -Amyloid: A Disease Target or a Synaptic Regulator Affecting Age-Related Neurotransmitter Changes?
Current Pharmaceutical Design The Psychopharmacology of European Herbs with Cognition-Enhancing Properties
Current Pharmaceutical Design Impact of Apolipoprotein E on Alzheimer’s Disease
Current Alzheimer Research Comparative Study of Non-High Density Lipoproteins Cholesterol Level and Lipid Profile in Pre-Diabetic and Diabetic Patients
CNS & Neurological Disorders - Drug Targets Alzheimers Disease: From Pathogenesis to Disease-Modifying Approaches
CNS & Neurological Disorders - Drug Targets Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Nanotechnology Driven Approaches for the Management of Parkinson’s Disease: Current Status and Future Perspectives
Current Drug Metabolism mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Dolichol: A Natural Biomarker of Aging Endowed With a Photoenhanced Highly-Effective Solar Filter Activity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies
Current Alzheimer Research Lithium - Pharmacological and Toxicological Aspects: The Current State of the Art
Current Medicinal Chemistry